| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/24/2000 | EP1002534A1 Bis-Staurosporine and K-252a derivatives |
| 05/24/2000 | EP1002083A1 Aprotinin variants with improved properties and bikunins of aprotinin variants |
| 05/24/2000 | EP1001985A1 Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| 05/24/2000 | EP1001979A1 Cyclic azapeptides with angiogenic effect |
| 05/24/2000 | EP1001978A1 Angiotensin derivatives |
| 05/24/2000 | EP1001976A2 Peptides having potassium channel opener activity |
| 05/24/2000 | EP1001974A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001973A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001972A1 Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001971A1 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001970A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1001965A1 Tissue plasminogen activator-like protease |
| 05/24/2000 | EP1001956A1 New 2,3-benzodiazepine derivatives |
| 05/24/2000 | EP1001946A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES |
| 05/24/2000 | EP1001945A1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES |
| 05/24/2000 | EP1001935A1 Indole derivatives as mcp-1 receptor antagonists |
| 05/24/2000 | EP1001933A1 Caspases and apoptosis |
| 05/24/2000 | EP1001805A1 Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof |
| 05/24/2000 | EP1001795A1 Vasoprotective recombinant adenovirus vector containing a human tfpi gene |
| 05/24/2000 | EP1001777A1 Fibrinogen receptor antagonists |
| 05/24/2000 | EP1001774A1 Use of phospholamban inhibitors to increasing coronary flow |
| 05/24/2000 | EP1001768A1 Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
| 05/24/2000 | EP1001766A1 Compounds and methods |
| 05/24/2000 | EP1001764A1 Heterocyclic amide compounds as cell adhesion inhibitors |
| 05/24/2000 | EP1001755A2 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| 05/24/2000 | EP0793674B1 Human neutrophil elastase inhibitors |
| 05/24/2000 | EP0637315B1 Adenosine derivatives having a2 agonist activity |
| 05/24/2000 | EP0626969B1 CoA-IT AND PAF INHIBITORS |
| 05/24/2000 | CN1254345A Serine protease inhibitors |
| 05/24/2000 | CN1254344A Estrogenic 10-Noradnrost-17-one derivatives with aromatic B-ring |
| 05/24/2000 | CN1254337A N-hydroxy 4-sulfonyl butyramide compounds |
| 05/24/2000 | CN1254284A Activated protein C formulations |
| 05/24/2000 | CN1254255A Methods for reducing fibrinogen |
| 05/24/2000 | CN1253827A Medicine for curing cardiac disease and its preparation method |
| 05/24/2000 | CN1253815A Preparation for external application for curing hypertension and hyperlipemia and its preparation method |
| 05/24/2000 | CN1253813A Medicine composition for curing angiocardiopathy and cerebrovascular disease and its preparation method |
| 05/24/2000 | CN1253778A Injection for curing hemorrhoid complicated by anal fistula and its preparation method |
| 05/24/2000 | CN1253775A Refractory vasculitis therapeutic preparation |
| 05/24/2000 | CN1052723C Bicyclic aromatic compounds as therapeutic agents, its preparing method and drug composition containing said compound |
| 05/24/2000 | CN1052653C Chinese medicine for curing coronary heart disease |
| 05/24/2000 | CN1052638C 'Xiaofengtong' injection and its preparing method |
| 05/23/2000 | US6066717 RsbW-1 protein |
| 05/23/2000 | US6066673 Enzyme inhibitors |
| 05/23/2000 | US6066662 Use in control or prevention of rheumatoid arthritis and osteoarthritis or in the treatment of invasive tumours, atherosclerosis or multiple sclerosis |
| 05/23/2000 | US6066657 For the treatment of disease states associated with proteins which mediate cellular activity, for example by inhibiting tumor necrosis factor or phosphodiesterase iv |
| 05/23/2000 | US6066655 For the treatment of central nervous system disorders, in particular as cerebral therapeutics |
| 05/23/2000 | US6066650 Inhibitors of microsomal triglyceride transfer protein and method |
| 05/23/2000 | US6066644 Treatment of various cns disorders |
| 05/23/2000 | US6066642 For selectively blocking the a3 adenosine receptor of a mammal |
| 05/23/2000 | US6066633 Prevent tissue degradation |
| 05/23/2000 | US6066502 Endothelin converting enzyme (ECE) |
| 05/23/2000 | CA2200959C 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives |
| 05/18/2000 | WO2000028554A1 Products and methods for brachytherapy |
| 05/18/2000 | WO2000028332A1 Methods and compositions to lower plasma cholesterol levels |
| 05/18/2000 | WO2000028323A1 Methods for identifying modulators of bs69 activity |
| 05/18/2000 | WO2000028027A2 Corticosteroid synthesis-associated genes |
| 05/18/2000 | WO2000028020A2 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor |
| 05/18/2000 | WO2000028010A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 05/18/2000 | WO2000027879A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 05/18/2000 | WO2000027868A2 Connective tissue growth factor (ctgf) and methods of use |
| 05/18/2000 | WO2000027866A1 Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof |
| 05/18/2000 | WO2000027850A2 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | WO2000027845A1 Spiro-indolines as y5 receptor antagonists |
| 05/18/2000 | WO2000027832A2 Thiazole derivatives as ppar gamma ligands |
| 05/18/2000 | WO2000027822A2 Tricyclic pyrazole derivatives |
| 05/18/2000 | WO2000027819A2 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | WO2000027815A2 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands |
| 05/18/2000 | WO2000027808A1 N-arylsulfonyl amino acid omega amides |
| 05/18/2000 | WO2000027805A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 05/18/2000 | WO2000027802A1 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 05/18/2000 | WO2000027432A1 USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS |
| 05/18/2000 | WO2000027422A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | WO2000027418A2 A method for treating tissue damaged from ischemia |
| 05/18/2000 | WO2000027414A2 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | WO2000027395A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
| 05/18/2000 | WO2000027392A1 Chromone enteric release formulation |
| 05/18/2000 | WO2000027387A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis |
| 05/18/2000 | WO2000027380A2 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 05/18/2000 | WO2000027377A2 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/18/2000 | WO2000027363A1 Aerosols comprising nanoparticle drugs |
| 05/18/2000 | WO2000027359A1 An inhalation system |
| 05/18/2000 | WO2000027189A1 Perfusion and/or preservation and/or re-perfusion solution during organ transplant |
| 05/18/2000 | WO2000009672A9 Dnazymes and methods for treating restenosis |
| 05/18/2000 | WO2000008202A3 3-methylidenyl-2-indolinone modulators of protein kinase |
| 05/18/2000 | WO2000008141A3 Short oligonucleotides for the inhibition of vegf expression |
| 05/18/2000 | WO2000008140A3 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/18/2000 | WO2000007544A3 Vitronectin receptor antagonists |
| 05/18/2000 | WO2000004892A3 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| 05/18/2000 | WO1999058096A3 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| 05/18/2000 | CA2351063A1 A system for administering a bioactive agent by inhalation comprising a lipid mixture comprising phosphatidylcholine |
| 05/18/2000 | CA2350915A1 Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof |
| 05/18/2000 | CA2350714A1 Spiro-indolines as y5 receptor antagonists |
| 05/18/2000 | CA2350316A1 Methods and compositions to lower plasma cholesterol levels |
| 05/18/2000 | CA2350235A1 Tricyclic pyrazole derivatives |
| 05/18/2000 | CA2350211A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
| 05/18/2000 | CA2350208A1 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | CA2350183A1 Use of an enterobacterium protein ompa for specific targeting towards antigen-presenting cells |
| 05/18/2000 | CA2350182A1 Connective tissue growth factor (ctgf) and methods of use |
| 05/18/2000 | CA2350133A1 A method for treating tissue damaged from ischemia |
| 05/18/2000 | CA2350086A1 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor |